Multiple myeloma (MM) is a common hematologic malignancy characterized by clonal plasma cell proliferation. Despite significant therapeutic advancements with proteasome inhibitors, immunomodulatory ...

Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated ...

Recent studies highlight the potential of minimal residual disease (MRD) testing to influence treatment decisions in multiple myeloma and chronic lymphocytic leukemia. Testing for minimal residual ...

TORONTO -- Achieving minimal residual disease (MRD) negativity was associated with favorable safety outcomes and no effect on health-related quality of life among patients with newly diagnosed ...

Turmeric (Curcuma longa) is a popular spice known for its intense yellow color. Studies suggest that curcumin, the active ingredient in turmeric, can help with weight loss due to its antioxidant and ...

The LINKER-SMM1 trial evaluates linvoseltamab's safety and efficacy in high-risk smoldering multiple myeloma, aiming to delay disease progression. At the 22nd International Myeloma Society annual ...

TORONTO -- A three-drug combination involving the B-cell maturation antigen (BCMA)-CD3 bispecific antibody elranatamab (Elrexfio) was associated with high response rates and manageable toxicity in ...

Multiple myeloma diagnosis integrates blood tests, genetic assessments, and imaging to guide personalized treatment and patient engagement. Smoldering multiple myeloma involves active surveillance to ...

More than 600 studies and 30+ late-breaking presentations showcase breakthroughs in myeloma and cancer care as 3,000 global experts gather in Toronto. TORONTO--(BUSINESS WIRE)--The International ...

Department of Hematology, The Eighth Affiliated Hospital, Southern Medical University (The First People’s Hospital of Shunde, Foshan), Foshan, China Background: Multiple myeloma (MM) is characterized ...